Check out the latest #TAPUR study paper in #JCOPO: Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Read the full article: https://bit.ly/4cVvaUU
A heartfelt ‘thank you’ to the innovator and longtime leader of our #TAPUR Study, Dr. Richard Schilsky, who will transition into his new role as Founding Principal Investigator of TAPUR in 2026. We are grateful for his leadership and contributions over many, many years.
Check out ASCO's grand rounds featuring the #TAPUR clinical trial. Open to all--learn more about this pragmatic trial seeking to find new uses for already approved targeted therapies and how you can take part. society.asco.org/sites/new-ww...
